Imfinzi

Active Ingredient(s): Durvalumab
FDA Approved: * May 1, 2017
Pharm Company: * ASTRAZENECA UK LTD
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Imfinzi Overview

Durvalumab[1] is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[2] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease pr...

Read more Imfinzi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Durvalumab

Recent Imfinzi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Durvalumab
  • Injection: 50mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Imfinzi: (2 results)

Sorted by National Drug Code
  • 0310-4500 Imfinzi 120 mg/2.4ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp
  • 0310-4611 Imfinzi 500 mg/10ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Durvalumab or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 21 November 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.